Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 20, 1996

View Archived Issues

New macrocyclic immunosuppressants from Abbott

Nippon Kayaku R&D pipeline update

Company Profile: Progenitor, Inc.

Warner-Lambert claims lipid-regulating agents for vascular disease, diabetes

SKB reports D3-selective antipsychotic agents

Analgesic kappa-opioid agonists reported by Pfizer

New farnesyl protein transferase series synthesized at Merck & Co.

Fujisawa describes new agents for thrombocytopenia

FPTase inhibitior series reported by Schering-Plough

400-C, new FPTase inhibitor reported by Schering-Plough

Johns Hopkins University reports antiproliferative vitamin D3 analogue

Tanabe to develop marimastat

TBC-11251 enters clinical trials

Peripheral opiate antihyperalgesic from Adolor in clinical trials

Sanofi introduces new platinum complex

Potential of clotrimazole in the treatment of diarrhea

Pharming granted orphan drug status for Pompe's disease therapy

Pfizer's antiasthma drug R&D

Oculex dexamethasone intraocular delivery system superior to eye drops

Cel-Sci receives Japanese patent for HGP-30 technology

Xylitol chewing gum effective in preventing otitis media

Ansan starts new development program for chemotherapy-induced alopecia

HRT for preserving bone density in postmenopausal women

Immunoregulating effect of IL-4 in IDDM

Recombinant NOVOMAb-G2 as potential cancer diagnostic

Antimigraine drug from Vanguard to enter pivotal trials

First pivotal trial for panic disorder Rx

Cephalon/Leo neurological disease collaboration

LTB4-PPARalpha as a new target for drug design

Pharmadigm (formerly Paradigm Biosciences) reports progress on lead therapeutic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...